Financial Performance - In 2023, the revenue of Zhong Ji Longevity Science Group was HK$64,989,000, a decrease of 27.5% compared to HK$89,668,000 in 2022[13]. - The profit attributable to the owners of the Company for 2023 was HK$2,313,000, recovering from a loss of HK$904,000 in 2022[13]. - For FY2023, the Group recorded total revenue of approximately HK$64,989,000, a decrease of 27.5% from HK$89,668,000 in FY2022[45]. - The profit for FY2023 amounted to approximately HK$2,523,000, compared to a profit of HK$701,000 in FY2022[45]. - The longevity science business generated revenue of approximately HK$31,326,000, down from HK$43,920,000 in FY2022, resulting in a segment loss of approximately HK$24,016,000[48]. - Revenue from diagnostic consultation and medical testing was approximately HK$26,879,000, showing stability compared to HK$26,370,000 in FY2022[53]. - Revenue from the sales of longevity biological products decreased to approximately HK$4,447,000 from HK$17,550,000 in FY2022 due to customs clearance delays[52]. - The money lending and financial advisory business recorded segment revenue of approximately HK$33,663,000, down from HK$45,748,000 in FY2022, with a segment profit of approximately HK$25,354,000[56]. - The Group's consolidated net assets as of December 31, 2023, were approximately HK$430,465,000, an increase from HK$420,849,000 in FY2022[46]. - Basic and diluted earnings per share for FY2023 were approximately HK$0.15, compared to a loss per share of HK$0.06 in FY2022[46]. Strategic Goals and Expansion - The Company aims to achieve a leading position in global sales revenue of lipid-lowering biological products by 2024[20]. - The "ZJ1 VC sustained-release tablet" product is now available for sale to over 50 million consumers in 117 countries[20]. - The Company is committed to establishing a world-leading longevity science transformation and application platform[18]. - The strategy includes expansion through joint ventures, mergers, and acquisitions, focusing on brand building and industry-finance integration[18]. - The Group aims to achieve global leadership in the sales revenue of lipid-lowering biological products by 2024, with the competitive product ZJ1 VC sustained in over 117 countries for more than 50 million users[22]. - The Company is expanding its longevity management services in 26 major cities worldwide, enhancing its brand image as a preferred platform for high net-worth individuals[24][28]. - The Group plans to focus on the development and expansion of its longevity science business, which is expected to drive future revenue growth[55]. Operational Efficiency and Quality - The Company is focusing on enhancing operational efficiency and quality while refining its industry and product chains[19]. - The Group's strategic focus includes improving operational quality and efficiency in the longevity management field, amidst a challenging economic environment[25][29]. - The Group's financial performance is being enhanced through diversification into promising longevity medical health businesses[30][41]. - Increased marketing, advertising, and promotion expenses for the longevity science business amounted to approximately HK$19,105,000 during FY2023[48]. - The Group aims to operate under a light asset model to reduce operational pressure and risk while expanding its longevity science business[162]. Investment and Financial Position - Investment properties increased to HK$25,295,000 in 2023 from HK$24,411,000 in 2022, reflecting a growth of 3.2%[16]. - The total shareholders' equity as of December 31, 2023, was HK$430,465,000, up from HK$420,849,000 in 2022, indicating a growth of 1.5%[16]. - The Group's fair value of equity securities listed on the Stock Exchange decreased to approximately HK$5,847,000 as of 31 December 2023, down from HK$9,859,000 as of 31 December 2022[61]. - The Independent Recovery Committee successfully recovered HK$30,000,000 from a borrower entity, negotiating the recovery of previously impaired loans totaling approximately HK$1,076,000,000[60]. - The Group's gearing ratio as of December 31, 2023, was approximately 1.6%, unchanged from December 31, 2022[148]. - The Group did not pledge any assets to banks or other financial institutions as of December 31, 2023, nor did it have any corporate guarantees[146]. Management and Governance - The executive team includes Mr. Yan Li, who has over 8 years of experience in advanced medical and biological technology management, and Mr. Yan Yifan, who has been with the company since April 2022[174][175]. - The management team has extensive experience in corporate management and business operations, with members holding significant positions in various organizations[179][180]. - The board includes non-executive directors with significant experience in innovation and investment consulting, enhancing the company's strategic direction[184][185]. - The company emphasizes the importance of risk management and has established several committees to oversee this aspect[188]. - The board includes members with significant experience in auditing, accounting, and financial management, enhancing the company's governance structure[188]. - The company aims to strengthen its market position through strategic appointments and governance improvements[189]. Loan and Borrower Management - The Group manages over 14 corporate and personal borrower loans, with principal sizes ranging from approximately HK$47.9 million for personal borrowers to HK$64.4 million for corporate loans[109]. - As of December 31, 2023, the corporate and personal borrowers business loan assets were approximately HK$819,455,000 before impairments, slightly up from HK$819,403,000 in 2022[113]. - The net carrying value of these loan assets was approximately HK$177,732,000, an increase from HK$172,289,000 in the previous year[113]. - The top five borrowers accounted for approximately 79.93% of the total loan and interest receivables of the Group as of December 31, 2023, consistent with the previous year[113]. - The loan leverage ratio for collateralized loans ranged from 31.79% to 74.69%, secured by properties, financial assets, and dividend rights[113]. - The Group has initiated recovery actions on previously impaired loans, indicating a proactive approach to asset management[113]. Shareholder and Capital Management - The total number of issued shares of the Company increased from 4,257,112,915 shares to 4,554,412,915 shares following the placement of 297,300,000 new shares at a price of HK$0.049 per share[71]. - The Company approved a share consolidation on 2 August 2023, consolidating every ten issued and unissued ordinary shares into one consolidated share, resulting in a total of 455,441,291 issued shares[77]. - As of December 31, 2023, the total number of issued shares was 455,441,291, with a par value of HKD 0.01 per share, reflecting an increase from 425,711,291 shares in the previous fiscal year after the share consolidation[80]. - The Company successfully placed a total of 29,730,000 new shares at a placing price of HK$0.49 on May 2, 2023, resulting in net proceeds of approximately HK$14.0 million[163]. - The Group aims to strengthen its financial position through effective use of capital raised from the Placing[171]. Research and Development - The Asian Integrated Cell Laboratory under HK Zhong Ji 1 is recognized as the world's leading autoimmune cell bank, indicating a strong position in the biotechnology sector[174]. - The company is focused on integrating leading resources for knee joint health globally, which includes cell testing, storage, and gene therapies[174]. - The company has a strategic focus on advanced biomedical technology, with key executives having backgrounds in both business and healthcare sectors[180]. - The company is focused on innovation and scientific research, as evidenced by the involvement of leading experts in its management team[195].
中基长寿科学(00767) - 2023 - 年度财报